GOSSAMER BIO, INC. Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One
GOSSAMER BIO, INC. (GOSS) had Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One of $265.52 million as of 2024-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Notes › Debt and Equity Securities › Available-for-Sale Securities, Debt Maturities
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue · last filed 2025-03-13
- 2024-12-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $265.52M.
- 2023-12-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $264.32M.
- 2022-12-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $143.71M.
- 2021-12-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $141.81M.
| Period end | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One |
|---|---|
| 2024-12-31 | $265.52M 10-K · filed 2025-03-13 |
| 2023-12-31 | $264.32M 10-K · filed 2024-03-05 |
| 2022-12-31 | $143.71M 10-K · filed 2023-03-17 |
| 2021-12-31 | $141.81M 10-K · filed 2022-03-03 |
| 2020-12-31 | $26.57M 10-K · filed 2021-02-26 |
| 2019-12-31 | $237.45M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |